publication . Other literature type . Article . 2009

Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation.

Sally-Ann Cryan; Clifford Taggart;
Open Access
  • Published: 21 Aug 2009
  • Publisher: Informa UK Limited
  • Country: United Kingdom
Abstract
Secretory leukocyte protease inhibitor (SLPI) is an endogenous serine protease inhibitor that protects the lungs from excessive tissue damage caused by leukocyte proteases released during inflammation. Recombinant SLPI (rSLPI) has shown potential as a treatment for inflammatory lung conditions. To date, its clinical application has been limited by rapid enzymatic cleavage by cathepsins and rapid clearance from the lungs after inhalation. In this study, rSLPI was encapsulated in 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine] : Cholesterol (DOPS : Chol) liposomes for inhalation. Incubation of rSLPI with cathepsin L leads to complete loss of activity while encapsulat...
Subjects
free text keywords: Physical and Theoretical Chemistry, Colloid and Surface Chemistry, Organic Chemistry, Bioengineering, Pharmaceutical Science
Related Organizations
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue